



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



8th Data Sheet

CONFIRMATION NO. 3385

SERIAL NUMBER 10/842,970	FILING DATE 08/18/2003 RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. DEA V2002/0063 US NP
-----------------------------	-----------------------------------	--------------	------------------------	---

## APPLICANTS

Olaf Ritzeler, Bad Soden, GERMANY;

Gerhard Jaehne, Frankfurt, GERMANY;

## \*\* CONTINUING DATA \*\*

This appln claims benefit of 60/434,749 12/19/2002  
*VL*

## \*\* FOREIGN APPLICATIONS \*\*

GERMANY 10237722.7 08/17/2002  
*VL*

## IF REQUIRED, FOREIGN FILING LICENSE GRANTED

\*\* 11/11/2003

Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	STATE OR	SHEETS	TOTAL	INDEPENDENT
35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	COUNTRY	DRAWING	CLAIMS	CLAIMS
Verified and Acknowledged Examiner's Signature <i>[Signature]</i> Initials <i>VL</i>	GERMANY	0	14	1

## ADDRESS

Julie Anne Knight  
Aventis Pharmaceuticals, Inc.  
Patent Department  
Route #202-208/ P.O. Box 6800  
Bridgewater, NJ  
08807-0800

## TITLE

Indole derivatives or benzimidazole derivatives for modulating I $\kappa$ B kinase

FILING FEE	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees ( Filing )
		<input type="checkbox"/> 1.17 Fees ( Processing Ext. of time )

BEST AVAILABLE COPY

9/14/2005 5:08:12 PM

RECEIVED 880	No. _____ for following:	<input type="checkbox"/> 1.18 Fees ( Issue )
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit _____

BEST AVAILABLE COPY

9/14/2005 5:08:12 PM